BioSpace News Archive

Exasol, the high-performance analytics database, announced that Pharmascience Inc., a leading Canadian manufacturer of prescription, over-the-counter, and behind-the-counter generic pharmaceuticals, has selected Exasol to give end-users faster, more efficient access to data.

According to the World Health Organization, 13.6 percent of patients diagnosed with COVID-19 experienced a headache, often described as moderate to severe in intensity, many of which “may feel like a migraine attack.” Not only is headache one of the signs of the COVID-19 virus, it is also recognized as a lingering symptom long after the illness is over.

-2021 Expected to be a Banner Year for Advancing Three Product Platforms in the Clinic: -Mino-Lok® Interim Efficacy Analysis -Halo-Lido filing IND and in Phase 2b trial -Mino-Wrap™ in Pre-Clinical Development, targeting IND by end of year

Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that Kristen Miranda has been appointed to its Board of Directors, effective March 1, 2021. In addition, Ms. Miranda was appointed to the Board’s Compensation Committee.

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that it will be presenting on direct saliva testing for COVID-19 at the 28th Annual International Molecular Medicine Tri-Conference, held virtually on February 16-18, 2021.

Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announced that it is presenting at the BIO CEO & Investor Digital Conference, 16-18 th February 2021.

The groundbreaking viral genome sequencing and reflex testing solution identifies various COVID-19 variant strains, enabling employers, health plans, and public health agencies to optimize surveillance, treatment and vaccination protocol to mitigate spread of the virus more effectively.

This production step is one of a series of steps in the project plan to manufacture batches of Tryp’s proprietary formulation of cGMP psilocybin to support the company’s clinical development and for the company’s upcoming clinical trials.

While BioMark Diagnostic Solutions is preparing to offer lab services and metabolomics capabilities in Quebec City to accelerate commercialization of its assays, the Quebec-based Phytronix will bring its experience in high-throughput analysis, automated sample preparation and assay development to this collaboration.

Gilead Will Provide $5 Million in Grant Funding to Wake Forest Over 3 Years as Part of the Gilead COMPASS Initiative® in the Southern United States